Prognostic Factors After Pancreatectomy for Pancreatic Cancer Initially Metastatic to the Liver.
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
23
03
2022
accepted:
28
07
2022
pubmed:
18
8
2022
medline:
11
11
2022
entrez:
17
8
2022
Statut:
ppublish
Résumé
Resection of initially oligometastatic pancreatic ductal adenocarcinoma (PDAC) following response to first-line chemotherapy is controversial. We herein updated a previous case series to investigate the oncologic outcomes and preoperative factors that could drive the decision-making process. This retrospective analysis was limited to patients with liver-only synchronous metastases who experienced complete regression of the metastatic component and underwent pancreatectomy between October 2008 and July 2020 at two high-volume institutions. Clinical-pathologic variables were captured, and inflammation-based prognostic scores were calculated. Recurrence and survival analyses were performed using standard statistical methods. Overall, 52 patients were included. FOLFIRINOX was the most employed chemotherapy regimen (63.5%). Post-treatment tumor size, serum carbohydrate antigen (CA) 19-9 and carcinoembryonic antigen (CEA) were significantly decreased relative to baseline evaluation. The median time from diagnosis to pancreatectomy was 10.2 months, while the median time from chemotherapy completion to pancreatectomy was 2 months. Major postoperative complications occurred in 26.9% of patients, while postoperative mortality was nil. The median disease-free survival (DFS) and overall survival (OS) from pancreatectomy were 16.5 and 23.0 months, respectively, and the median OS from diagnosis was 37.2 months. At multivariable analysis, vascular resection, operative time, prognostic nutrition index (PNI) and neutrophil-to-lymphocyte ratio (NLR) were associated with OS. Operative time, platelet × neutrophil/lymphocyte count (SII), and PNI were associated with DFS. We confirm promising outcomes of selected patients who underwent pancreatectomy following downstaging of liver metastases. The absence of vascular involvement of the primary tumor, good nutritional status, and low inflammatory index scores could be useful to select candidates for resection.
Sections du résumé
BACKGROUND
BACKGROUND
Resection of initially oligometastatic pancreatic ductal adenocarcinoma (PDAC) following response to first-line chemotherapy is controversial. We herein updated a previous case series to investigate the oncologic outcomes and preoperative factors that could drive the decision-making process.
METHODS
METHODS
This retrospective analysis was limited to patients with liver-only synchronous metastases who experienced complete regression of the metastatic component and underwent pancreatectomy between October 2008 and July 2020 at two high-volume institutions. Clinical-pathologic variables were captured, and inflammation-based prognostic scores were calculated. Recurrence and survival analyses were performed using standard statistical methods.
RESULTS
RESULTS
Overall, 52 patients were included. FOLFIRINOX was the most employed chemotherapy regimen (63.5%). Post-treatment tumor size, serum carbohydrate antigen (CA) 19-9 and carcinoembryonic antigen (CEA) were significantly decreased relative to baseline evaluation. The median time from diagnosis to pancreatectomy was 10.2 months, while the median time from chemotherapy completion to pancreatectomy was 2 months. Major postoperative complications occurred in 26.9% of patients, while postoperative mortality was nil. The median disease-free survival (DFS) and overall survival (OS) from pancreatectomy were 16.5 and 23.0 months, respectively, and the median OS from diagnosis was 37.2 months. At multivariable analysis, vascular resection, operative time, prognostic nutrition index (PNI) and neutrophil-to-lymphocyte ratio (NLR) were associated with OS. Operative time, platelet × neutrophil/lymphocyte count (SII), and PNI were associated with DFS.
CONCLUSIONS
CONCLUSIONS
We confirm promising outcomes of selected patients who underwent pancreatectomy following downstaging of liver metastases. The absence of vascular involvement of the primary tumor, good nutritional status, and low inflammatory index scores could be useful to select candidates for resection.
Identifiants
pubmed: 35976466
doi: 10.1245/s10434-022-12385-4
pii: 10.1245/s10434-022-12385-4
pmc: PMC9383677
doi:
Substances chimiques
CA-19-9 Antigen
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
8503-8510Informations de copyright
© 2022. Society of Surgical Oncology.
Références
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 202. CA Cancer J Clin. 2022;72:7–33.
doi: 10.3322/caac.21708
pubmed: 35020204
Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. Lancet. 2020;395:2008–20.
doi: 10.1016/S0140-6736(20)30974-0
pubmed: 32593337
Shrikhande SV, Kleeff J, Reiser C, et al. Pancreatic resection for M1 pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2006;14:118–27.
doi: 10.1245/s10434-006-9131-8
pubmed: 17066229
Antoniou E, Margonis GA, Sasaki K, et al. Is resection of pancreatic adenocarcinoma with synchronous hepatic metastasis justified? A review of current literature. ANZ J Surg. 2016;86:973–7.
doi: 10.1111/ans.13738
pubmed: 27580713
Buc E, Orry D, Antomarchi O, Gagnière J, Da Ines D, Pezet D. Resection of pancreatic ductal adenocarcinoma with synchronous distant metastasis: is it worthwhile? World J Surg Oncol. 2014;12:347.
doi: 10.1186/1477-7819-12-347
pubmed: 25407113
pmcid: 4289271
Tachezy M, Gebauer F, Janot M, et al. Synchronous resections of hepatic oligometastatic pancreatic cancer: disputing a principle in a time of safe pancreatic operations in a retrospective multicenter analysis. Surgery. 2016;160:136–44.
doi: 10.1016/j.surg.2016.02.019
pubmed: 27048934
Hackert T, Niesen W, Hinz U, et al. Radical surgery of oligometastatic pancreatic cancer. Eur J Surg Oncol. 2017;43:358–63.
doi: 10.1016/j.ejso.2016.10.023
pubmed: 27856064
Tao L, Yuan C, Ma Z, Jiang B, Xiu D. Surgical resection of a primary tumor improves survival of metastatic pancreatic cancer: a population-based study. Cancer Manag Res. 2017;9:471–9.
doi: 10.2147/CMAR.S145722
pubmed: 29056856
pmcid: 5635848
Oweira H, Petrausch U, Helbling D, et al. Prognostic value of site-specific metastases in pancreatic adenocarcinoma: a surveillance epidemiology and end results database analysis. World J Gastroenterol. 2017;23:1872–80.
doi: 10.3748/wjg.v23.i10.1872
pubmed: 28348494
pmcid: 5352929
Zhou W, Wang D, Lou W. Current role of surgery in pancreatic cancer with synchronous liver metastasis. Cancer Control. 2020;27:1073274820976593.
doi: 10.1177/1073274820976593
pubmed: 33238715
pmcid: 7791445
Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.
doi: 10.1056/NEJMoa1011923
pubmed: 21561347
Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–703.
doi: 10.1056/NEJMoa1304369
Kandel P, Wallace MB, Stauffer J, et al. Survival of patients with oligometastatic pancreatic ductal adenocarcinoma treated with combined modality treatment including surgical resection: a pilot study. J Pancreat Cancer. 2018;4:88–94.
doi: 10.1089/pancan.2018.0011
pubmed: 30631861
pmcid: 6319614
Crippa S, Bittoni A, Sebastiani E, et al. Is there a role for surgical resection in patients with pancreatic cancer with liver metastases responding to chemotherapy? Eur J Surg Oncol. 2016;42:1533–9.
doi: 10.1016/j.ejso.2016.06.398
pubmed: 27423449
Byun Y, Han Y, Kang JS, et al. Role of surgical resection in the era of FOLFIRINOX for advanced pancreatic cancer. J Hepato-Biliary-Pancreat Sci. 2019;26:416–25.
doi: 10.1002/jhbp.648
Tanaka M, Heckler M, Mihaljevic AL, et al. CT response of primary tumor and CA19-9 predict resectability of metastasized pancreatic cancer after FOLFIRINOX. Eur J Surg Oncol. 2019;45:1453–9.
doi: 10.1016/j.ejso.2019.03.039
pubmed: 30981446
Wright GP, Poruk KE, Zenati MS, et al. Primary tumor resection following favorable response to systemic chemotherapy in stage IV pancreatic adenocarcinoma with synchronous metastases: a bi-institutional analysis. J Gastrointest Surg. 2016;20:1830–5.
doi: 10.1007/s11605-016-3256-2
pubmed: 27604886
Nie D, Lai G, An G, et al. Individualized prediction of survival benefits of pancreatectomy plus chemotherapy in patients with simultaneous metastatic pancreatic cancer. Front Oncol. 2021;11:719253.
doi: 10.3389/fonc.2021.719253
pubmed: 34604055
pmcid: 8481362
Frigerio I, Regi P, Giardino A, et al. Downstaging in stage IV pancreatic cancer: a new population eligible for surgery? Ann Surg Oncol. 2017;24:2397–403.
doi: 10.1245/s10434-017-5885-4
pubmed: 28516291
Crippa S, Cirocchi R, Weiss MJ, et al. A systematic review of surgical resection of liver-only synchronous metastases from pancreatic cancer in the era of multiagent chemotherapy. Updates Surg. 2020;72:39–45.
doi: 10.1007/s13304-020-00710-z
pubmed: 31997233
De Simoni O, Scarpa M, Tonello M, et al. Oligometastatic pancreatic cancer to the liver in the era of neoadjuvant chemotherapy: Which role for conversion surgery? A systematic review and meta-analysis. Cancers. 2020;12:3402.
doi: 10.3390/cancers12113402
pmcid: 7698586
Bassi C, Marchegiani G, Dervenis C, et al. The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After. Surgery. 2017;161:584–91.
doi: 10.1016/j.surg.2016.11.014
pubmed: 28040257
Wente MN, Veit JA, Bassi C, et al. Postpancreatectomy hemorrhage (PPH)–an international study group of pancreatic surgery (ISGPS) definition. Surgery. 2007;142:20–5.
doi: 10.1016/j.surg.2007.02.001
pubmed: 17629996
Wente MN, Bassi C, Dervenis C, et al. Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. 2007;142:761–8.
doi: 10.1016/j.surg.2007.05.005
pubmed: 17981197
Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.
doi: 10.1097/01.sla.0000133083.54934.ae
pubmed: 15273542
pmcid: 1360123
Jabłońska B, Pawlicki K, Mrowiec S. Associations between nutritional and immune status and clinicopathologic factors in patients with pancreatic cancer: a comprehensive analysis. Cancers. 2021;13:5041.
doi: 10.3390/cancers13205041
pubmed: 34680194
pmcid: 8533745
Edge SB, Byrd DR, Compton CC, et al editors. AJCC Cancer Staging Manual. 7th edn. New York: Springer; 2010.
Pausch TM, Liu X, Cui J, et al. Survival benefit of resection surgery for pancreatic ductal adenocarcinoma with liver metastases: a propensity score-MAtched SEER database analysis. Cancers. 2021;14:57.
doi: 10.3390/cancers14010057
pubmed: 35008223
pmcid: 8750488
Tsai S, George B, Wittmann D, et al. Importance of normalization of CA19-9 levels following neoadjuvant therapy in patients with localized pancreatic cancer. Ann Surg. 2020;271:740–7.
doi: 10.1097/SLA.0000000000003049
pubmed: 30312198
Reni M, Zanon S, Balzano G, et al. Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma. Ann Oncol. 2017;28:2786–92.
doi: 10.1093/annonc/mdx495
pubmed: 28945895
Maggino L, Malleo G, Marchegiani G, et al. Outcomes of primary chemotherapy for borderline resectable and locally advanced pancreatic ductal adenocarcinoma. JAMA Surg. 2019;154:932–42.
doi: 10.1001/jamasurg.2019.2277
pubmed: 31339530
pmcid: 6659151
Kleive D, Sahakyan MA, Berstad AE, et al. Trends in indications, complications and outcomes for venous resection during pancreatoduodenectomy. Br J Surg. 2017;104:1558–67.
doi: 10.1002/bjs.10603
pubmed: 28815556
Belfiori G, Fiorentini G, Tamburrino D, et al. Vascular resection during pancreatectomy for pancreatic head cancer: a technical issue or a prognostic sign? Surgery. 2021;169:403–10.
doi: 10.1016/j.surg.2020.08.002
pubmed: 32912782
Nakagawa K, Sho M, Akahori T, et al. Significance of the inflammation-based prognostic score in recurrent pancreatic cancer. Pancreatology. 2019;19:722–8.
doi: 10.1016/j.pan.2019.05.461
pubmed: 31153778
Ahmad J, Grimes N, Farid S, Morris-Stiff G. Inflammatory response related scoring systems in assessing the prognosis of patients with pancreatic ductal adenocarcinoma: a systematic review. Hepatobiliary Pancreat Dis Int. 2014;13:474–81.
doi: 10.1016/S1499-3872(14)60284-8
pubmed: 25308357
Perlmutter BC, Ali J, Turgut BC, et al. Correlation between physical status measures and frailty score in patients undergoing pancreatic resection. Surgery. 2022;171:711–7.
doi: 10.1016/j.surg.2021.10.030
pubmed: 34848074